These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 28831241)

  • 1. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
    Guasti L; Gaudio G; Lupi A; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Sarzani R; Vanasia M; Maffioli P; Derosa G
    Drug Des Devel Ther; 2017; 11():2293-2300. PubMed ID: 28831241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
    Derosa G; Maffioli P; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Guasti L; Sarzani R; Bestetti A; Vanasia M; Gaudio G;
    Cardiovasc Ther; 2017 Feb; 35(1):47-54. PubMed ID: 27860389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative Efficacy of the Influence of Fixed Combinations of Antihypertensive Drugs That Block the Renin-Angiotensin-Aldosterone System, With Thiazide Diuretics on the Parameters of Ambulatory Blood Pressure Monitoring].
    Ostroumova OD; Garelik IA
    Kardiologiia; 2016 Dec; 56(12):20-26. PubMed ID: 28290800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice.
    Mazza A; Lenti S; Schiavon L; Sacco AP; Dell'Avvocata F; Rigatelli G; Ramazzina E
    Adv Ther; 2017 Apr; 34(4):975-985. PubMed ID: 28299716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
    Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
    Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
    Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
    J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
    Kereiakes DJ; Neutel J
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide.
    Guerrero P; Fuchs FD; Moreira LM; Martins VM; Bertoluci C; Fuchs SC; Gus M
    Clin Exp Hypertens; 2008 Oct; 30(7):553-64. PubMed ID: 18855259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
    Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.